Get Started

RPRX

NASD Royalty Pharma Plc Class A
Oct 24, 2026 · 4:58 AM ET EOD Market Closed

$63.86 ↑ +0.00 (+0.00%) Trading Up from the previous close of $63.86, $0.11 below the day’s high of $63.97

YTD change
+65.27%
vs 20-day SMA
+8.86%
vs 200-day SMA
+21.69%

Price ranges

Previous day
$63.01 $63.97
open $63.34 close $63.86
+$0.52 (+0.82%)
Today
$63.01 $63.97
$63.86
Past week
$59.62 $63.84
from $59.62 now $63.86
+$4.24 (+7.11%)
Past month
$55.13 $63.84
from $58.29 now $63.86
+$5.57 (+9.56%)
This year
$38.29 $64.38
from $38.64 now $63.86
+$25.22 (+65.27%)

Price & Performance

+14.48 (+29.32%) / 6M

$48.21$53.85$59.49$65.13Apr 24Jul 27Oct 23

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 0.8% away from all-time highs of $64.38
  • RPRX is up 65% since the beginning of the year
  • RPRX is up 73% over the past 12 months
  • RPRX is up 10% over the past 1 month
  • 3% of all RPRX investors are betting against RPRX

RPRX reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +71.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $1.32136
Earnings momentum -11.9% Quarterly EPS growth
Quarterly change -11.9%

Valuation

P/E ratio 33.06
Enterprise value $46.6B
Beta 0.47

Balance sheet & scale

Income$815.0K
Revenue$2.5B
Cash$837.0M
Debt$9.0M
Income / Debt 0.09×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Real Estate and Rental and Leasing
Sub Sector Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
Market cap $28.4B

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Competitor comparison

TickerCompany PriceChange
QSR.CAT RESTAURANT BRANDS INTL INC $105.58 -1.41%
TPL Texas Pacific Land Corporation $338.26 +1.38%
LORL.CAT LOREAL S.A. CIBC CDR CAD HED $28.05 N/A
PREKF PrairieSky Royalty Ltd $26.18 +1.28%
WH Wyndham Hotels & Resorts, Inc. $72.42 -3.53%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.